Inovio initiates cervical cancer clinical trial Inovio Pharmaceuticals announced it has initiated a phase I/IIa clinical trial to evaluate safety, immunogenicity, clinical responses and disease-free survival of its DNA immunotherapy product, INO-3112, in treating human papillomavirus-associated cervical cancer. INO-3112 is a combination of Inovio's immunotherapy product, VGX-3100, and its immune activator expressing interleukin-12. VGX-3100 is currently being evaluated in a randomized phase II efficacy trial for the treatment of high grade cervical dysplasia.
News For INO From The Last 14 Days
Check below for free stories on INO the last two weeks.